Anaesthetic implications and transfusion practices in ABO incompatible living donor liver transplantation: Case series

Sindhu Balakrishnan, Lakshmi Kumar, Divya Daniel, Sudhindran Surendran
Departments of Anaesthesiology and Critical Care and Gastrointestinal and Solid Organ Transplant, Amrita Institute of Medical Sciences, Amrita Vidyashram, Kochi, Kerala, India

ABSTRACT

ABO incompatible liver transplants (ABOi LT) are considered as a life-saving option when compatible donor grafts are unavailable. Fourteen adults (right lobe graft) and three children (left lateral segment/lobe) who underwent ABOi LT from living donors between 2011 and 2020 period were analysed for transfusions and desensitisation protocols. All recipients received packed red blood cells (PRBC) of their own group. AB plasma that does not contain any antibody was transfused in eight patients and donor group plasma in others. None of the patients developed transfusion related complications. Plasmapheresis and rituximab/bortezomib desensitisation was practised in 11 patients, only rituximab in four, only plasmapheresis in one, and no treatment in a 1 year child. Rejection was manifest in three patients while nine patients developed infections and sepsis. A working knowledge of the blood and product transfusions in ABOi LT is crucial for the anaesthesiologist. Perioperative management and impact of desensitisation protocol are discussed.

Key words: ABO incompatibility, liver transplantation, living donors

INTRODUCTION

With growing awareness of the feasibility of living donor liver transplantation, options for survival in end-stage liver disease (ESLD) patients has progressed. Non-availability of group matched altruistic living donors results in challenges in some patients. Introduction of successful desensitisation protocols offers ABO incompatible liver transplants (ABOi LT) as an option when group matched donors are unavailable. There is little published literature on the anaesthetic management of patients undergoing ABOi LT.

Seventeen patients who underwent ABO iLT between 2011 and 2017 were included. The arrangement of blood products was as per the protocol. Packed red cells belonging to Group O and plasma of Group AB have no antigens. Platelets are mildly antigenic by virtue of the plasma in which they are transfused. Major incompatibility refers to the presence of recipient antibody against the donor red blood cells while in minor incompatibility donor antibodies are directed against recipient red cells which can lead to haemolysis and passenger lymphocyte syndrome which is usually self-limiting. Bidirectional incompatibility refers to the presence of both types of incompatibilities.
**CASE DESCRIPTION**

**Case 1-3**

Case 1 was a 1-year-old with biliary atresia post Kasai who did not receive desensitisation but who developed vascular complications post-surgery. Case 2 was a 5 year old with acute liver failure (ALF) of indeterminate aetiology and underwent one cycle of rituximab, while case 3 was a 12 year ALF who received rituximab and two cycles of plasmapheresis [Table 1]. Case 2 received a lateral segment graft and case three left lobe graft, both patients developed sepsis relating to desensitisation postoperatively. Transfusion details are shown in Table 2.

**Cases 4-6**

Three adult patients with ALF, case four was rat poison induced and cases five and six, acute viral hepatitis underwent ABOiLT. All received rituximab or bortezumab, case four received two cycles of plasmapheresis and case six one cycle. Cell-mediated rejection (ACR) was seen in case four and antibody-mediated rejection (AMR) in case five. All patients received blood matched to recipient blood group and AB plasma. Platelets and cryoprecipitate transfusions were in accordance to the donor group [Table 2].

**Cases 7-17**

Eleven adult patients underwent ABOiLT for chronic liver disease and received right lobe grafts from living donors. Cases 10 and 16 received only rituximab while case 13 only plasmapheres while the other patients received a combination of both. Case 10 developed ACR while cases 7, 8, and 12 developed sepsis from overwhelming immunosuppression. Transfusions are shown in Table 2. Packed red blood cell (PRBC) transfusions varied between 4 and 18 and were recipient blood group. Plasma was AB + in five patients, and donor blood group matched in the rest. Platelet and cryoprecipitate transfusions were according to the donor group [Table 2]. Two patients developed major bleeding complication in the first 6 weeks following transplant.

All patients who underwent transplant were induced by a standard anaesthetic technique with lorazepam (0.05 mg/kg), propofol (2-2.5 mg/kg), fentanyl (2 µg/kg) and cis-atracurium (0.15 mg/kg) or suxamethonium 1.5 mg/kg. Prostaglandin E 1 (PGE1/Alprostadil) was infused at a rate of 0.25 µg/kg/h after reperfusion and continued for 96 h postoperatively. Patients were extubated 12–16 h after surgery. The pattern of immunosuppression was similar to that in compatible transplants and consisted of tacrolimus, mycophenolate, and steroids. Tacrolimus dosing was titrated to maintain a trough level of 5–10 ng/ml. Mycophenolate was maintained at between 1,000 and 1,500 mg/day. Steroids were given at 500, 250, 125, and 75 mg on days 1–4, and maintained at 20 mg/day.

---

**Table 1: Details of ABO iLT and desensitisation protocols**

| No. | Age (years) | Gender | Aetiology | MELD/PELD | Wt. kg | Graft | GW/RW | Isoagglutinin titre (IgG: IgM) | R: NOC | P: NOC | Complication |
|-----|-------------|--------|-----------|-----------|--------|-------|-------|---------------------------------|--------|--------|--------------|
| Paediatric |
| 1  | 1           | F      | CLD       | 24        | 8      | LLS   | 3.7   | 0: 8                            | -      | -      | Sepsis,      |
| 2  | 5           | F      | ALF       | 36        | 12     | LLS   | 2.0   | 16:64                           | 1      | -      | ACR, AMR,    |
| 3  | 12          | F      | ALF       | 40        | 31     | LL    | 0.75  | NA                              | 1      | 2      | Sepsis       |
| Adult ALF |
| 4  | 23          | M      | ALF       | 35        | 75     | RL+MHV| 0.90  | 64:64                           | 1      | 2      | Sepsis,      |
| 5  | 48          | M      | ALF       | 40        | 79     | RL+MHV| 0.81  | 4:32                            | 1      | -      | AMR, HAT,    |
| 6  | 24          | M      | ALF       | 36        | 55     | RL+MHV| 1.1   | 2: 32                           | B**    | 1      | Sepsis       |
| Adult CLD |
| 7  | 56          | M      | CLD       | 34        | 78     | RL+MHV| 0.73  | 64:64                           | 2      | 3      | Sepsis,      |
| 8  | 55          | M      | CLD       | 31        | 54     | RL+MHV| 1.1   | 64:128                          | 2      | 1      | Sepsis,      |
| 9  | 44          | M      | CLD       | 28        | 50     | RL+MHV| 0.7   | 1:64                            | 1      | 1      | Sepsis,      |
| 10 | 40          | F      | CLD       | 18        | 71     | RL+MHV| 0.84  | 4:32                            | 1      | -      | ACR          |
| 11 | 37          | M      | CLD       | 26        | 68     | RL+MHV| 0.96  | 16:256                          | 1      | 1      | Sepsis       |
| 12 | 52          | M      | CLD       | 28        | 72     | RL+MHV| 0.86  | 2:8                             | 1      | 1      | Sepsis       |
| 13 | 47          | M      | CLD       | 19        | 51     | RL+MHV| 1.5   | 32:64                           | -      | 1      | Sepsis       |
| 14 | 50          | M      | CLD       | 28        | 82     | RL+MHV| 0.76  | 64:128                          | 1      | 1      | Sepsis       |
| 15 | 50          | M      | CLD       | 21        | 74     | RL+MHV| 0.72  | 512: 512                        | 1      | 2      | Sepsis,      |
| 16 | 59          | M      | CLD       | 18        | 53     | RL+MHV| 0.95  | 16: 64                          | 1      | -      | Intracerebral bleed |
| 17 | 50          | M      | CLD       | 28        | 57     | RL+MHV| 0.96  | 32: 8                           | 1      | 2      | Gastrointestinal bleed |

CLD: Chronic liver disease; ALF: Acute liver failure; LLS: Left lateral segment; LL: Left lobe; RL+MHV: Right lobe;middle hepatic vein; GW: RW: Graft weight/recipient weight ratio; R NOC: Rituximab, number of cycles; PNOC: Plasmapheresis, number of cycles; B **: Bortezumab; ACR: Cell mediated rejection; AMR: Antibody mediated rejection
and tapered at 3 months. Protocols were modified based upon rejection or presence of side effects.

**DISCUSSION**

We looked at the transfusion practices amongst ABOi LT with a view to formulate clearer guidelines during transfusions. We did not follow-up beyond the stay in the intensive care unit (ICU) as our primary concerns were related to the anaesthesia, transfusions, and immediate intensive care although a longer follow-up would have provided more insights on management. Among the 17 patients in our group, major ABO incompatibility was seen in 14 patients, bidirectional incompatibility in three patients.[8] The transfusion protocol was as per recommended guidelines.[6,7] While AB plasma is the first choice as it contains no antibodies, donor group plasma is acceptable in the background of non-availability. The recommendations for platelets and cryoprecipitate are to be of the donor group to minimise reactions following transfusion. Rhesus (Rh) compatibility should be adhered to during transfusion. In an event that Rh + blood is transfused to a Rh − patient, then Rh immunoglobulins should be administered particularly for a female in the reproductive age group. Packed red blood cells (PRBC) should be Rh-compatible with the recipient’s blood group and platelet concentrate, fresh frozen plasma, and cryoprecipitate should be Rh-compatible with that of the donor.[6]

The consequences of ABO incompatibility are graft rejection and haemolytic complications. Rejection has been described as hyperacute, acute, and chronic and is because of the recipient antibody against the donor antigens. A high incidence of infections in the initial part of the programme appeared to decrease with less aggressive desensitisation protocols in the later part of the programme.[8]

The basis of administering PGE1 is to improve the hepatic arterial blood flow, accelerate recovery of mitochondrial function and stabilise the membrane micro viscosity.[1,9] Prostaglandin E1 also decreases the cell mediated cytotoxicity against the hepatocytes and enhances the level of DNA synthesis in cell by stimulating the cyclic adenosine monophosphate production and increasing the ATP level in hepatic tissue.[10] All our patients included had infusions of Prostaglandin E1 administered intravenously at 0.25 µg/kg/h that we believed could enhance graft blood flow.

Rituximab acts by a reduction of precursor cells responsible for clonal expansion during AMR.[11] Our current strategy involves administration of a single dose of rituximab 375 mg/m² body surface area or less, 1–4 weeks prior to the ABOi LT.

---

Table 2: Blood product use in ABO incompatible transplants

| Donor group | Recipient Group | PRBC Group | FFP Group | Group | SDP Nos | Cryoprecipitate |
|-------------|----------------|------------|-----------|-------|---------|----------------|
| Pediatric   |                |            |           |       |         |                |
| 1.*         | B+             | O+         | 0.5       | B+    | 1       | B+ 1          |
| 2.*         | A+             | O+         | 1         | A+    | 4       | A+ 2.5        |
| 3.*         | B+             | O+         | 4         | AB+   | 4       | AB+ 3.5       |
| Adult ALF   |                |            |           |       |         |                |
| 4*          | AB+            | B+         | 4         | AB+   | 4       | AB+ 1        |
| 5*          | A-             | O+         | 3         | AB+   | 10      | A+ 2         |
| 6*          | AB+            | A+         | 7         | AB+   | 15      | AB 2.2 R     |
| Adult CLD   |                |            |           |       |         |                |
| 7 *         | B+             | O+         | 18        | AB+   | 16      | B+ 10 R, 2 37 |
| 8 *         | B+             | O+         | 6         | AB+   | 8       | AB+ 5 R 20   |
| 9 °         | A+             | B+         | 5         | AB+   | 5       | AB+ 1,14 R 5 |
| 10°         | AB+            | B+         | 4         | AB+   | 5       | AB+ 10       |
| 11°         | B-             | O+         | 4         | AB+   | 11      | B+ 5         |
| 12°         | A2+            | B+         | 11        | A+    | 7       | AB+          |
| 13°         | A+             | O+         | 12        | A+    | 11      | A+ 2         |
| 14°         | B+             | A+         | 4         | B+    | 9       | B 8 R       |
| 15°         | A2+            | O+         | 7         | A+    | 3       | A+ 1, 4 R 14 |
| 16°         | B+             | O+         | 5         | B+    | 3       | B 0.5       |
| 17°         | A-             | O+         | 16        | A+    | 14      | A+ 10       |

*Major incompatibility. °Bidirectional Incompatibility. R: Random donor platelets, CLD: Chronic liver disease, ALF: Acute liver failure
The blood group A2+ among donors is unique in that it is associated with lower antigen expressivity than the A1 group. Skogsberg et al. presented 10 patients belonging to group O who received grafts from A2+ deceased donors managed without plasmapheresis, immune absorption or splenectomies preoperatively with an 80% graft survival. Kluger et al. have shown that A2 grafts could survive well even in the presence of a high anti-A or anti-B antibody titre. In our experiences with two such donors, the first recipient underwent both plasmapheresis and rituximab and succumbed to sepsis perhaps from overaggressive desensitisation which may not have been needed with an A2+ graft. The second did receive both plasmapheresis and single dose of rituximab and made an uneventful recovery. With the current knowledge, desensitisation can perhaps be minimised with A2+ donors to avoid side effects of excessive desensitisation.

Children less than 2 years are believed to have decreased immune responses and comparable results with compatible liver transplants are reported. This has been attributed to the decreased immune responses in children, reducing the rejection. Only one child less than 2 years underwent ABOi LT in our group but succumbed to graft failure following technical issues with vascular anastomosis. Haemolytic complications from passenger lymphocyte syndrome and increased incidence of biliary strictures are associations of ABOi LT.

The desensitisation protocol may carry a risk of excessive immunosuppression that makes the recipient predisposed to infections. Meticulous asepsis in the care of the patient postoperatively is indicated. The use of postoperative steroids as immunosuppression can enhance this vulnerability. Postoperative management involves care of patients with special attention to immunosuppression and graft function and vigilance for infection and biliary tract dysfunctions as they are more prone to complications.

CONCLUSIONS

ABOi LT has evolved as viable treatment strategy in ESLD patients with unavailability of group matched living donors. Meticulous attention to group matched products, attention to asepsis and anticipation of specific problems relating to desensitisation and biliary problems is essential for the anaesthesiologist or intensivist in providing the best supportive care and enhancing outcomes.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Dahlgren US, Bennet W. ABO-incompatible liver transplantation – A review of the historical background and results. Int Rev Immunol 2019;38:118-28.
2. Hanto DW, Fecteau AH, Alonso MH, Valent G, Whiting JF. ABO-incompatible liver transplantation with no immunological graft losses using total plasma exchange, splenectomy, and quadruple immunosuppression: Evidence for accommodation. Liver Transpl 2003;9:22-30.
3. Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S, Kadozuma T, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 2002;73:1959-61.
4. Trust Clinical Guidelines Group. Leeds teaching Hospital. Guidelines for blood component and blood product provision during solid organ transplantation. Available from: http://leedsth.nhs.uk. [Last accessed on 2021 Feb 22].
5. Watz E, Remberger M, Rindlen O, Lundahl J, Ljungman P, Mattsson J, et al. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. Bio Blood Marrow Transplant 2014;20:264-71.
6. Onouphridou D, Kelley W, Klein H, Flegel AW. Recommendations for transfusion in ABO-incompatible hematopoietic stem cell transplantation. Transfusion 2012;52:456-8.
7. Green L, Bolten-Maggps P, Beattie C, Cardigan R, Kattis Y, Stanworth SJ, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: Their handling and use in various patient groups in the absence of major bleeding. Br J Haematol 2018;181:54-67.
8. Shahahan S, Sasadhan T, Surendran S, Shenoy V, Padma UD. Lessons learnt from living donor liver transplantation with ABO-incompatibility: A single-centre experience from southern India. Indian J Gastroenterol 2019;38:23-8.
9. Nakamura Y, Matsuno N, Iwamoto H, Yokoyama T, Kuzuoka K, Kihara Y, et al. Successful case of adult ABO-incompatible liver transplantation: Beneficial effects of intrahepatic artery infusion therapy: A case report. Transplant Proc 2004;36:2269-73.
10. Bharaithan VK, Chandran B, Gopalakrishnan U, Varghese CT, Menon RN, Balakrishnan D, et al. Perioperative prostaglandin e1 infusion in living donor liver transplantation: A double-blind, placebo-controlled randomized trial. Liver Transpl 2016;22:1067-74.
11. Egawa H, Umeshita K, Uemoto S. Optimal dosage regimen for rituximab in ABO-incompatible living donor liver transplantation. J Hepatobiliary Pancreat Sci 2017;24:89-94.
12. Skogsberg U, Breimer ME, Friman S, Mjornstedt L, Molne J, Olsson L, et al. Successful ABO-incompatible liver transplantation using A2 donors. Transplant Proc 2006;38:2667-70.
13. Kluger MD, Guarrera JV, Olesen SK, Brown RS Jr, Emond JC, Cherquei D, et al. Safety of blood group A2-to-O liver transplantation: An analysis of the united network of organ sharing database. Transplantation 2012;94:526-31.
14. Rana A, Kuehl ML, Nicholas SK, Jindra PT, Himes RW, Desai MS, et al. Pediatric liver transplantation across the ABO blood group barrier: Is it an obstacle in the modern era? J Am Coll Surg 2016;222:681-9.
15. Song GW, Lee SG, Hwang S, Kim KH, Ahn CG, Moon DB, et al. Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era. J Hepatol 2014;61:575-82.
### Appendix 1: Protocol for Blood and product transfusion in Major and Bidirectional Incompatibility[^5,^7,^12]

| Recipient group | Antibody in the recipient | Donor group | PRBC | FFP | Platelets | Cryoprecipitate |
|-----------------|---------------------------|-------------|------|-----|-----------|----------------|
| O               | Anti A anti B             | A           | O    | AB  | A         | A, AB          |
| O               | Anti A anti B             | B           | O    | AB  | B         | AB, A, O, B, AB|
| O               | Anti A anti B             | AB          | O    | AB  | A         | A, B, O        |
| A               | Anti B                    | AB          | A/O  | AB  | A         | A, B, O        |
| B               | Anti A                    | AB          | B/O  | AB  | B         | A, B, O        |
| B               | Anti A                    | A           | B/O  | AB  | A         | A, B, O        |
| A               | Anti B                    | B           | A/O  | AB  | B         | A, B, O        |

PRBC: Packed red blood cells, FFP: Fresh frozen plasma

### Appendix 2: Definition of major and minor ABO Incompatibility

| Recipient Blood Group | Donor Blood Group |
|-----------------------|-------------------|
| Major ABO incompatible |                   |
| O                     | A                 |
| O                     | B                 |
| O                     | AB                |
| A                     | AB                |
| B                     | AB                |

| Minor ABO incompatible |                   |
|------------------------|-------------------|
| A                      | O                 |
| B                      | O                 |
| AB                     | O                 |
| AB                     | A                 |
| AB                     | B                 |

| Bidirectional Incompatible |       |
|-----------------------------|-------|
| A                           | B     |
| B                           | A     |